American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

JAK Inhibitors: "Life is Good, Stable is Good"

Dr. Srdan Verstovsek discusses the benefits of being treated with JAK inhibitors.

Read more

Factor XI Antisense: A Challenge to Common Sense

Dr. Adam Cuker challenges some common notions of Factor XI.

Read more

Sickle Cell Trait: More Bad News for the Kidneys?

Dr. Charles Quinn discusses how sickle cell trait affects the kidneys.

Read more
View All

Presidents Column

Dr_ David A_ Williams - Presidents Column

David A. Williams, MD

Chief of Hematology/Oncology; Director of Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts
Earnest Support for Careers and Cures
February 24, 2015

Dr. Williams shines a spotlight on the scholarships and awards ASH makes possible each year, and the successes of the numerous winners.

View All

Clinical Trials Corner

Can Prolyl Hydroxylase Inhibition Treat EPO-Deficient Anemia of Renal Failure With Fewer Vascular Complications Than EPO Itself?
February 12, 2015

A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients.

View All

Ask The Hematologist

Ask the Hematologist: Treatment of Elderly Patients with Acute Myeloid Leukemia
January 22, 2015

Dr. Medeiros discusses his approach to treating elderly patients with acute myeloid leukemia.

View All

Mini Review

Labile Iron: Potential Toxicity in Iron Overload Disorders
February 13, 2015

Iron homeostasis relies on a regulated network of systemic and cellular mechanisms for the acquisition, transportation and cellular utilization of the metal.1 Once in inner body fluids, iron is swiftly captured by a chemically shielded vehicle (transferrin) that circulates and safely delivers it to cells commensurate with their metabolic needs. In the cellular milieu, most of the iron is also protein-associated, either directly or via heme or iron-sulfur-cluster moieties.

View All

Op Ed

Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?”
November 19, 2014

Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.

View All
  • New Oncology Care Model Released by Center for Medicare and Medicaid Innovation

    On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer.  Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016.  Click on the headline to read more.

  • ASH Comments on FDA Draft Guidance for Laboratory Developed Tests

    On January 30, ASH submitted comments on the Food and Drug Administration's (FDA) Draft Guidance  on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs).  The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs.  Click on the link above to read more about ASH's comments.

  • ASH Comments on NIH Single IRB Policy

    On January 28, The American Society of Hematology (ASH) submitted comments  on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH.  The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB.  Read more to learn about ASH's stance on the policy.

  • ODAC Recommends Approval of First Biosimilar Drug

    The Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended the approval of the first application for a biosimilar drug on January 7.  The panel recommended that FDA approve the application for a biologic agent similar to filgrastim.  This drug would be used for a number of applications in hematology.

View all policy news
back to top